(Q43165902)

15 November 2017

title

Lck is a key target of imatinib and dasatinib in T-cell activation (English)

1 reference

15 November 2017

main subject

dasatinib monohydrate

1 reference

1 reference

1 reference

K C Lee

1

1 reference

15 November 2017

I Ouwehand

2

1 reference

15 November 2017

A L Giannini

3

1 reference

15 November 2017

N S Thomas

4

1 reference

15 November 2017

N J Dibb

5

1 reference

15 November 2017

M J Bijlmakers

6

1 reference

15 November 2017

publication date

11 February 2010

1 reference

15 November 2017

1 reference

15 November 2017

volume

24

1 reference

15 November 2017

issue

4

1 reference

15 November 2017

page(s)

896-900

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2010.11

15 November 2017

exact match

0 references

cites work

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

Regulation of the Src family kinase Lck by Hsp90 and ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.11

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.11

1 reference

Dimensions Publication ID

15 November 2017

1046949857

0 references

1 reference